Date: 2015-09-10
Type of information: Subvention
Company: Tyromab consortium
Investors: FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France)
Amount: € 1.57 million
Funding type: subvention
Planned used: The TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) consortium is headed by ElsaLys Biotech and supported by PX’Therapeutics, the Aguettant pharmaceuticals group’s bioproduction subsidiary, and Centre Léon Bérard. The TYROMAB project seeks to validate an anti-TYRO3 antibody candidate against leiomyosarcoma and metastatic bladder cancer. It's also aiming to reduce production costs for this antibody. These two products should hit the market 3 to 5 years after the start of the FUI project for the drug candidate (sale of an exclusive license to a biopharmaceutical laboratory) and at the end of the collaborative project for the bioproduction system, i.e. at the end of the year 2018.
Others: * On September 10, 2015, ElsaLys Biotech announced that the FUI (Fonds Unique Interministériel – Single Interministerial Fund) has granted a € 1.57 million subsidy to the Tyromab (TYROsine kinase receptor Monoclonal AntiBody) project. The Tyromab project has been labels jointly from two competitiveness clusters – Alsace BioValley and Lyonbiopôle – and receives support from the French government, Europe’s ERDF fund, the Rhône-Alpes Region, the Alsace Region, Strasbourg Eurométropole, Lyon la Métropole and Grenoble–Alpes Métropole.
Therapeutic area: Cancer - Oncology
